Pellegrino lists relative success rates of submissions to the FDA

Analysts understand the likelihood of success ties directly to a discount rate in valuing early-stage IP. With that in mind, Mike Pellegrino shared with BVR some FDA statistics that readers will find sobering.

Drugs targeting this disease group              Experience this success rate

arthritis                                                            20.4%

central nervous system                                  14.5%

cardiovascular                                                  17.5%

gastrointestinal                                                20.0%

immunology                                                    15.4%

infectious disease                                           28.1%

The new edition to Mike Pellegrino’s Guide to Intellectual Property Valuation is discussed here.